Clover Bio-B announced on the Hong Kong Stock Exchange on March 27 that the 2023 revenue was $39.255 million, stemming from the commercial listing of SCB-2019 (CpG1018/aluminum adjuvant) and quadrivalent seasonal influenza vaccines in China. These products were introduced to the market in February and September 2023, respectively, which contributed to revenue growth. The adjusted loss for the year was 85.24 million yuan, and the adjusted loss for the same period last year was 2,357 million yuan. During the reporting period, the company established commercial manufacturing capacity to produce and supply COVID-19 vaccines at its own production site in Changxing, Zhejiang. The company will continue to prioritize resources to accelerate the development of the RSV vaccine candidate to seize its rapidly growing market opportunities as soon as possible.